Medherant Ltd., a University of Warwick spin-out developing a novel transdermal drug delivery patch technology, is pleased to announce the appointment of Dr Ken Cunningham as Chair. Dr Cunningham joins Medherant as the company prepares to move into clinical studies with its leading TEPI Patch® technology.
Mon, 06/02/2017 - 07:30
Synpromics announces a research collaboration with GE Healthcare to Extend the Toolbox for Production of Biologics
Wed, 04/01/2017 - 07:30
Edinburgh, UK, 4th January 2017 / Sciad Newswire / Synpromics Ltd, the leading synthetic promoter and gene control compan
Prokarium and Probiomed in UK-Mexico Collaboration to Scale-Up Manufacture of Thermostable Vaccines with a Focus on Diarrhoea
Wed, 04/01/2017 - 07:00
Prokarium and Probiomed today announced the start of their collaboration to scale-up the manufacture of orally administered vaccines in a formulation that would enable stability at 40°C for several weeks. The first vaccine to be manufactured will be developed to prevent so-called ‘Montezuma’s revenge’ or diarrhoea, which affects the local population as well travellers in Mexico and many countries.
Wed, 07/12/2016 - 07:30
Synpromics Ltd, the leading synthetic promoter and gene control company, is pleased to expand the research collaboration with Adverum Biotechnologies that began in December 2015.
Mon, 24/10/2016 - 09:00
NALIA Systems, a developer of novel multiplex immunodiagnostic systems for clinical and research applications, announces the expansion of its board following the recent successful £500,000 fund raising.
Tue, 18/10/2016 - 14:45
London, UK, 18th October 2016 / Sciad Newswire / NALIA Systems, a developer of novel multiplex immunodiagnostic systems for clinical and research applications, ha
Tue, 04/10/2016 - 09:00
San Francisco, USA, 4th October 2016 / Sciad Newswire / Biologist and inventor of new transposase-based tool, Kate Caves discusses DNA2.0’s emerging cell engineer
Tue, 27/09/2016 - 09:00
Medherant Ltd., a University of Warwick spin-out developing a novel transdermal drug delivery patch technology, has completed a funding round worth £1.5M, including a direct investment of £650,000 from Mercia Technologies PLC.
Quorum Innovations announces availability of human microbiome therapeutics to treat common skin conditions and metabolic disorders
Wed, 21/09/2016 - 14:00
Probiomic Therapeutics™ for Eczema, Atopic Dermatitis, Eosinophilic Esophagitis (EoE), Metabolic Disorders
Wed, 22/06/2016 - 08:30
Results reveal key differences between digital health and other life science companies.